Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
about
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary diseaseβ(2) -adrenoceptor agonists: current and future directionCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseasePrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment ParadigmPredicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.COPD: maximization of bronchodilation.Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Indacaterol: a comprehensive review.Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes.Future of chronic obstructive pulmonary disease management.Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to dateBronchodilators, receptors and cross-talk: Together is better?Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
P2860
Q24186652-9B586463-231B-4483-9A90-92DA69564EE5Q24604047-4215BCBF-963D-4CE1-A247-E4AE10328DE5Q27012625-7FD7BD8D-2331-477E-987D-EB6DCDCC435CQ27348844-64C3EF0F-A346-4DC9-B38C-F10F5BFD5131Q28087788-B3955AF3-B5D2-488D-9710-C4C7FBECB09FQ34322908-5DFA2B0E-E945-4F31-9A4B-75007F298924Q34436393-5E9F051D-83D4-4680-97A3-BD14A85648FFQ34544020-6DA0E98E-37D9-4936-BB8D-FB5EFD9050D3Q35541687-9B066602-92FD-4FFD-8ADA-E993A3044E3BQ35703517-8AD92F10-0AF4-469A-BFE0-4FB375FEE2BBQ37057061-A243CF53-2F33-4716-A365-3038DF4B1539Q37247499-F4CD110E-4EC0-41C1-A4C8-F251C8224753Q37351371-F0F421ED-6F83-4F4F-9797-C7F882809ABCQ37468663-6086007B-BD9F-492C-9B2F-05F662F1CE95Q37573177-D480DC21-536F-44BC-9E6C-97D14BFBD8F5Q37867838-06A11961-8150-4CE9-9BA9-56687A48C249Q37973657-D36EA4D7-68FC-4B15-940C-F1BB26589FC4Q38025725-BA1D788F-3C43-4AD8-AC96-923E7C769AAAQ38051307-83640F55-EE12-4A3F-B885-9053F4FFD021Q38057220-FEE7DE4A-6CE3-4FB9-BDDA-6A373FD8F949Q38125210-45320018-8EAF-476C-869D-B0F15A3D380AQ38194114-FCE7D188-3727-4985-AA5E-F9D70A499951Q38204363-61BB48A7-5C52-4068-8C2F-AC8D9F23495EQ38359553-4CFA88A1-580C-47D8-BD41-3D5388F74251Q38371555-362E583E-22DD-4681-9C44-FE1052A85C52Q38406157-22A65BB2-1D5A-4BC1-A7B6-CA758866FFD1Q38432438-A088732C-BBA6-4910-BF85-2C25F341DFBEQ38570698-199E8B17-64AE-4E58-B194-AF0D1F858EEFQ38660895-C8CF0594-7ADF-42CF-B2E4-694942B73E11Q38754002-FE596DFD-6C28-4863-8D8C-E693488AC622Q41282858-FB1C5EDC-20EC-42F8-9EF2-C6C0450AB9ADQ50954570-4D27F8D7-DCB9-41D6-8CC0-283719CC4C97
P2860
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@en
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@nl
type
label
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@en
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@nl
prefLabel
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@en
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@nl
P2093
P2860
P1476
Cardiovascular safety of QVA14 ...... and NVA237, in COPD patients.
@en
P2093
Boudewijn Van de Maele
Carmen Martin
Michael Dolker
Rachael Horton
Tim Overend
P2860
P304
P356
10.3109/15412555.2010.528812
P407
P577
2010-12-01T00:00:00Z